PMID- 30543921
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 199
DP  - 2019 Feb
TI  - Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis.
PG  - 25-28
LID - S1521-6616(18)30714-9 [pii]
LID - 10.1016/j.clim.2018.12.006 [doi]
AB  - Systemic Sclerosis (SSc) is a rare autoimmune disease that is characterized by a 
      progressive skin fibrosis, an obliteration of the microvasculature and an 
      exaggerated extracellular matrix deposition, which lead to a multisystemic 
      dysfunction. Various pathogenetic mechanisms were described. The lack of a 
      successful therapy make SSc a disease with a poor prognosis. The intravenous 
      immunoglobulin (IVIG) has been used for a long time in different autoimmune 
      diseases, and firstly used in SSc patients in 2000. IVIG has multiple 
      non-specific mechanisms of action and, beyond an impressive improvement in muscle 
      symptoms, a French nationwide cohort demonstrated that IVIG ameliorates the skin 
      disease and systemic inflammation, and helps the daily dose corticosteroid's 
      tapering at the end of the treatment. The benefits on gastrointestinal symptoms 
      of IVIG was reported by a recent English article, in which the patients 
      consistently reported a decrease in the gastro-esophageal reflux disease symptoms 
      and their frequencies. The impact on the lung involvement still remains unclear. 
      One of the advantages of IVIG is its safe profile. Few adverse effects were 
      reported and most of them are mild, and can be managed and usually they do not 
      relapse. Harmful effects were described, but they can be avoid with cautious and 
      judicious use of this therapy.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Gomes, Joao Pedro
AU  - Gomes JP
AD  - Zabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Hashomer, 
      Israel; Department A of Internal Medicine, Hospital and University Centre of 
      Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Portugal. 
      Electronic address: jpcxl@hotmail.com.
FAU - Santos, Lelita
AU  - Santos L
AD  - Department A of Internal Medicine, Hospital and University Centre of Coimbra, 
      Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Portugal. 
      Electronic address: lelitasantos@netcabo.pt.
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
AD  - Sackler Faculty of Medicine, Tel Aviv University, Israel; Zabludowicz Center for 
      Autoimmune Disease, Sheba Medical Center, Tel Hashomer, Israel. Electronic 
      address: shoenfel@post.tau.ac.il.
LA  - eng
PT  - Journal Article
DEP - 20181210
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/adverse effects/pharmacology/*therapeutic use
MH  - Scleroderma, Systemic/*drug therapy
OTO - NOTNLM
OT  - Autoimmune diseases
OT  - Autoimmunity
OT  - Fibrosis
OT  - Intravenous immunoglobulins (IVIG)
OT  - Systemic sclerosis
EDAT- 2018/12/14 06:00
MHDA- 2019/12/04 06:00
CRDT- 2018/12/14 06:00
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2018/12/14 06:00 [entrez]
AID - S1521-6616(18)30714-9 [pii]
AID - 10.1016/j.clim.2018.12.006 [doi]
PST - ppublish
SO  - Clin Immunol. 2019 Feb;199:25-28. doi: 10.1016/j.clim.2018.12.006. Epub 2018 Dec 
      10.